Urelumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Urelumab
Accession Number
DB12077  (DB05960)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
BMS 663513 / BMS-663513 / BMS-66513
Categories
UNII
230902QLLC
CAS number
934823-49-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 9Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Urelumab.
AbituzumabThe risk or severity of adverse effects can be increased when Urelumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Urelumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Urelumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Urelumab.
AducanumabThe risk or severity of adverse effects can be increased when Urelumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Urelumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Urelumab.
AmatuximabThe risk or severity of adverse effects can be increased when Urelumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911279
Wikipedia
Urelumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentMelanoma (Skin) / Skin Cancers1
1Active Not RecruitingTreatmentNeoplasms Malignant1
1CompletedTreatmentB-Cell Malignancies1
1CompletedTreatmentCancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma1
1CompletedTreatmentColorectal Cancers / Head and Neck Carcinoma1
1CompletedTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentGlioblastomas / Gliosarcoma / Recurrent Brain Neoplasm1
1RecruitingTreatmentMalignancies1
1TerminatedTreatmentAdvanced Solid Malignancies1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentMelanoma1
1, 2CompletedTreatmentAdvanced B-cell NHL / Advanced Solid Tumors1
1, 2Not Yet RecruitingTreatmentNeoplasms1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentTumors1
2CompletedTreatmentMelanoma1
2RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
2WithdrawnTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
Gene Name
TNFRSF9
Uniprot ID
Q07011
Uniprot Name
Tumor necrosis factor receptor superfamily member 9
Molecular Weight
27898.6 Da

Drug created on October 20, 2016 15:18 / Updated on December 02, 2019 09:17